Company research
CITIUS ONCOLOGY, INC.
CIK 1851484Updated Nov 13, 2026
SecurityCTOR · NASDAQ · equity
Name history
TenX Keane Acquisition · through Aug 5, 2024
CTOR price & chart
Loading TradingView…
NASDAQ:CTOR on TradingView ↗About the company
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I - III CTCL after at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.
In the news
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) News provided by Purcell & Lefkowitz LLP Jan 05, 2026, 10:30 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowit ↗
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update News provided by Citius Oncology, Inc. Dec 23, 2025, 16:30 ET Share this article Share to X Share this article Share to X Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 ↗
Recent filings
4 filing
4 filing
4 filing
4 filing
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
Submission of Matters to a Vote of Security Holders
Items 5.07
ARS filing
DEF 14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 112,093,103Source | 91,709,079Source | — | 100,699,168Source | 91,439,365Source | — | 109,973,406Source | 90,481,481Source | 100,942,881Source | 84,368,878Source | 72,623,594Source | 68,190,364Source |
| Current assets: | ||||||||||||
| Inventory, NetUSD | 22,625,945Source | 17,208,967Source | — | 22,659,590Source | 15,339,253Source | — | 22,639,342Source | 14,381,369Source | 22,286,693Source | 8,268,766Source | — | — |
| Assets, CurrentUSD | 42,707,165Source | 18,309,079Source | — | 29,423,666Source | 18,039,365Source | — | 37,146,844Source | 17,081,481Source | 27,542,881Source | 10,968,878Source | 58,200Source | 377,344Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 71,708,109Source | 59,311,166Source | — | 65,430,399Source | 55,796,733Source | — | 51,559,705Source | 49,191,869Source | 56,076,650Source | 38,228,540Source | — | — |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 10,576Source | 7,155Source | — | 9,298Source | 7,155Source | — | 8,480Source | 7,155Source | 8,351Source | 7,155Source | 167Source | 242Source |
| Additional Paid in CapitalUSD | 145,481,984Source | 91,434,058Source | — | 131,443,191Source | 89,308,821Source | — | 127,979,246Source | 87,220,249Source | 108,897,836Source | 85,411,771Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -105,107,566Source | -59,043,300Source | — | -96,183,720Source | -53,673,344Source | — | -69,574,025Source | -45,937,792Source | -64,039,956Source | -39,278,587Source | -1,987,729Source | 345,266Source |
| Stockholders' Equity Attributable to ParentUSD | 40,384,994Source | 32,397,913Source | 17,030,861Source | 35,268,769Source | 35,642,632Source | 19,846,711Source | 58,413,701Source | 41,289,612Source | 44,866,231Source | 46,140,339Source | -1,987,562Source | 345,508Source |
| Liabilities and EquityUSD | 112,093,103Source | 91,709,079Source | — | 100,699,168Source | 91,439,365Source | — | 109,973,406Source | 90,481,481Source | 100,942,881Source | 84,368,878Source | 72,623,594Source | 68,190,364Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 58,787,194Source | 52,990,335Source | — | 58,812,298Source | 49,740,142Source | — | 44,710,394Source | 43,399,518Source | 49,491,579Source | 32,700,429Source | 2,045,762Source | 31,836Source |
| Accounts Payable, CurrentUSD | 7,315,516Source | 8,667,419Source | — | 8,883,239Source | 7,676,310Source | — | 10,446,900Source | 5,874,577Source | 13,234,684Source | 3,711,622Source | — | — |
| Deferred Income Tax Liabilities, NetUSD | 2,710,643Source | 2,520,720Source | — | 2,817,990Source | 2,256,480Source | — | 3,049,200Source | 1,992,240Source | 2,784,960Source | 1,728,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 25,836,120Source | 8,458,554Source | — | 24,057,573Source | 8,722,168Source | — | 4,518,916Source | 6,228,612Source | 4,093,124Source | — | 375,886Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 2,784,960Source | 1,728,000Source | — | — |
| Cash and Cash Equivalents, at Carrying Value | —Source | —Source | — | —Source | —Source | — | —Source | — | — | — | — | — |
| Accounts Receivable, after Allowance for Credit Loss, Current | —Source | — | — | —Source | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 3,560,791Source | 2,125,237Source | 3,526,710Source | 2,088,572Source | 3,956,050Source | 1,808,478Source | 8,320,419Source | 7,498,817Source | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 352,649Source | 6,112,603Source | 12,649,207Source | 2,133,871Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 264,240Source | 264,240Source | 1,056,960Source | 576,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,354,946Source | — | -5,492,046Source | 126,353Source | -601,304Source | -47,968Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -4,400,000Source | — | -5,750,000Source | -5,000,000Source | -1,320,000Source | -67,320,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 15,125,489Source | — | 15,166,842Source | 4,873,759Source | 1,664,875Source | 67,657,143Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | -256,429Source | 289,175Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 16,563,705Source | 112Source | 2,632,634Source | 112Source | 7,295,451Source | 112Source | 3,924,908Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 14,460Source | — | 187,389Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 2,125,237Source | — | 2,088,572Source | — | 1,808,478Source | 8,116,678Source | 7,498,817Source | — | — |
| General and Administrative ExpenseUSD | — | — | 4,219,163Source | 1,881,447Source | 23,625,639Source | 2,243,327Source | 2,859,339Source | 3,321,979Source | 8,783,997Source | 8,148,929Source | 1,013,070Source | 138,115Source |
| Income Tax Expense (Benefit)USD | — | — | -107,347Source | 264,240Source | -231,210Source | 264,240Source | 264,240Source | 264,240Source | 1,056,960Source | 576,000Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | 231,732Source | 160,755Source | 33,031Source | — | 45,841Source | — | 218,032Source | — | — | — |
| Investment Income, InterestUSD | — | — | 96,848Source | — | 43,721Source | — | 28,288Source | — | 36,373Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,923,846Source | -5,369,956Source | -26,609,695Source | -7,735,552Source | -5,534,069Source | -6,659,205Source | -24,761,369Source | -21,148,747Source | 2,419,304Source | 380,811Source |
| Noncash Merger Related CostsUSD | — | — | — | — | — | — | 2,753,795Source | 2,753,795Source | 2,753,795Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -314,376Source | -160,755Source | 1,772,690Source | — | -17,553Source | — | -181,659Source | — | 3,432,374Source | 518,926Source |
| Operating ExpensesUSD | — | — | 9,718,762Source | 4,944,961Source | 29,952,015Source | 7,471,312Source | 8,407,179Source | 6,394,965Source | 23,522,750Source | 20,572,747Source | — | — |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | — | 3,827,944Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 15,100,000Source | — | 15,166,842Source | — | — | 66,000,000Source |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Amortization of Debt Issuance Costs | — | — | —Source | — | — | — | — | — | — | — | — | — |
| Payments of Financing Costs | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -8,716,817Source | -4,944,961Source | -28,613,595Source | -7,471,312Source | -5,252,276Source | -6,394,965Source | -23,522,750Source | — | -1,013,070Source | -138,115Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -9,031,193Source | -5,105,716Source | -26,840,905Source | -7,471,312Source | -5,269,829Source | -6,394,965Source | -23,704,409Source | -20,572,747Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | -107,347Source | 264,240Source | -231,210Source | 264,240Source | 264,240Source | 264,240Source | 1,056,960Source | 576,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,923,846Source | -5,369,956Source | -26,609,695Source | -7,735,552Source | -5,534,069Source | -6,659,205Source | -24,761,369Source | -21,148,747Source | 2,419,304Source | 380,811Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.08Source | -0.08Source | -0.27Source | -0.11Source | -0.06Source | -0.09Source | -0.34Source | -0.31Source | 0.27Source | 0.12Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.08Source | -0.08Source | -0.27Source | -0.11Source | -0.06Source | -0.09Source | -0.34Source | -0.31Source | 0.27Source | 0.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 107,890,452Source | 71,552,402Source | 100,027,204Source | 71,552,402Source | 87,462,385Source | 71,552,402Source | 73,267,969Source | 68,053,607Source | 6,600,000Source | 1,865,478Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 107,890,452Source | 71,552,402Source | 100,027,204Source | 71,552,402Source | 87,462,385Source | 71,552,402Source | 73,267,969Source | 68,053,607Source | 6,600,000Source | 1,341,758Source |
| Interest Expense (non-operating)USD | — | — | 231,732Source | 160,755Source | 33,031Source | — | 45,841Source | — | 218,032Source | — | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 4,219,163Source | 1,881,447Source | 23,625,639Source | 2,243,327Source | 2,859,339Source | 3,321,979Source | 8,783,997Source | 8,148,929Source | 1,013,070Source | 138,115Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | 218,032Source | — | — | — |
| Investment Income, InterestUSD | — | — | 96,848Source | — | 43,721Source | — | 28,288Source | — | 36,373Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -314,376Source | -160,755Source | 1,772,690Source | — | -17,553Source | — | -181,659Source | — | 3,432,374Source | 518,926Source |
| Operating ExpensesUSD | — | — | 9,718,762Source | 4,944,961Source | 29,952,015Source | 7,471,312Source | 8,407,179Source | 6,394,965Source | 23,522,750Source | 20,572,747Source | — | — |
| Other ExpensesUSD | — | — | 27,939Source | 27,939Source | 27,939Source | 30,368Source | 27,939Source | 30,368Source | 114,185Source | 121,570Source | — | — |
| Other General and Administrative ExpenseUSD | — | — | 999,319Source | 567,937Source | 567,937Source | 567,937Source | 497,937Source | 567,937Source | 2,201,742Source | 1,846,202Source | 120,000Source | 21,666Source |
| Research and Development ExpenseUSD | — | — | 218,496Source | 938,277Source | 1,079,354Source | 3,139,413Source | 1,018,352Source | 1,264,508Source | 6,418,334Source | 4,925,001Source | — | — |
| Total Revenue | — | — | —Source | — | —Source | — | —Source | — | — | — | — | — |
| Cost of Goods and Services Sold | — | — | —Source | — | —Source | — | —Source | — | — | — | — | — |
| Gross Profit | — | — | —Source | — | —Source | — | —Source | — | — | — | — | — |
| Interest Expense, Debt | — | — | —Source | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-296360
Registration 333-292577
Registration 333-288656
- Gross proceeds
- 9000000.0
- Net proceeds
- 8370000.0
- Deal price
- 1.32
- Shares
- 6818182
- Offering price
- at-the-market
- Ticker
- CTOR
Filing attachments
ea031092801ex99-1.htm · 8-K · 2026-11-04
Exhibit 99.1 Citius Oncology’s Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin Patients who responded to LYMPHIR reported sustained improvement in skin-related quality of life measures CRANFOR…
Read attachment ↗ea030934701ex99-1.htm · 8-K · 2026-10-26
Exhibit 99.1 Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 CRANFORD, N.J., October 26, 2026 - Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR ® (denileukin diftitox…
Read attachment ↗ea030222601ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ea030222601ex99-1.htm PRESS RELEASE, DATED AUGUST 14, 2026 Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update $7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions ordering LYMPHIR ordered by 44 institutions since launch CRANFORD, N.J., August 14, 2026 /PRNewswire/ -- Citius Onc…
Read attachment ↗ea030145601ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 ea030145601ex99-1.htm PRESS RELEASE, DATED AUGUST 12, 2026 Exhibit 99.1 Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri CRANFORD, N.J., August 12, 2026 - Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph. D., J.D., as…
Read attachment ↗ea030037101ex99-1.htm · 8-K · 2026-08-05
EX-99.1 2 ea030037101ex99-1.htm PRESS RELEASE, DATED AUGUST 5, 2026 Exhibit 99.1 Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR’s near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., August 5, 2026 - Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncolog…
Read attachment ↗ea029290301ex99-1.htm · 8-K · 2026-06-01
EX-99.1 2 ea029290301ex99-1.htm PRESS RELEASE, DATED JUNE 1, 2026 Exhibit 99.1 Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated patien…
Read attachment ↗